診断用酵素の世界市場：現状分析・予測（2022年～2028年）

世界の診断用酵素の市場規模は、診断技術の革新の高まりや、酵素ベースの診断検査の採用が増加していることから、約4％で安定的に成長すると予測されています。また、様々な感染症や慢性疾患の有病率の上昇が、診断用酵素市場の主要な成長促進要因の1つです。

当レポートでは、世界の診断用酵素市場について調査分析し、セグメント別・地域別の市場洞察、市場力学、市場動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 市場イントロダクション

第2章 調査手法・前提条件

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 診断用酵素市場に対するCOVID-19の影響

第6章 診断用酵素市場収益（2020年～2028年）

第7章 市場洞察：タイプ別

• Taqポリメラーゼ
• RNase阻害剤
• Cas9酵素
• 酸性ホスファターゼ
• グルコースオキシダーゼ/グルコースデヒドロゲナーゼ
• ウレアーゼ
• 乳酸オキシダーゼ
• その他

第8章 市場洞察：用途別

• 感染症
• 自己免疫疾患
• 腫瘍学
• 心臓病学
• 腎臓学
• 糖尿病
• その他

第9章 市場洞察：製品タイプ別

• 分子酵素
• 臨床酵素

第10章 市場洞察：エンドユーザー別

• 病院
• 臨床検査室
• その他

第11章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• その他の地域

第12章 診断用酵素：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第13章 診断用酵素：市場機会

第14章 診断用酵素：市場動向

第15章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 企業概要

• Takara Bio, Inc.
• Promega Corporation
• Enzo Life Sciences, Inc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Creative Enzymes
• F. Hoffmann-La Roche Ltd.
• Solis BioDyne
• Ampliqon A/S
• Genzyme Corporation

第19章 免責事項

Enzymes are proteins with highly specialized catalytic functions, produced by all living organisms. The metabolic activity of all living creatures, including plants, microbes, animals, and mankind, depends on enzymes. Because of their excellent bio-catalytic properties, enzymes are frequently used in the detection of numerous disorders. Several metabolic problems can be caused by enzyme abnormalities. As a result, elements of the enzyme metabolism systems have been used as unique markers for the diagnosis of diseases. The prompt control of the transmission of infectious diseases and the reduction of the dangers to public health depends on the adoption of proper diagnostic enzyme techniques. Therefore, the rising prevalence of various infectious & chronic diseases is one of the major factors responsible for the growth of the diagnostic enzymes market. For instance, as per the World Health Organization 2020, the global impact of infectious disease by the SARS-CoV-2 outbreak (COVID-19), caused over 13.3 million infections and 782,000 deaths globally.

The Diagnostic Enzymes Market is expected to grow at a steady rate of around 4% owing to the increasing adoption of enzyme-based diagnostic tests coupled with the growing innovations in diagnostics technologies. Major players in the market offer innovative developments in the biotechnology domain with technologically advanced features. For instance, in January 2021, Creative Enzymes launched a complete product portfolio of diagnostic enzymes for medical and research diagnosis.

Based on type, the diagnostic enzymes market is segmented into Taq polymerase, RNase inhibitors, cas9 enzyme, acid phosphatase, glucose oxidase/glucose dehydrogenase, urease, lactate oxidase, and others. The glucose oxidase/glucose dehydrogenase segment accounted for a significant market share in 2020 owing to its several advantages such as its abundance, biocompatibility, and lack of toxicity. Furthermore, the entry of global players into emerging markets adds to the growth of the market during the forecast period.

On the basis of application, the diagnostic enzymes market is segmented into infectious diseases, autoimmune diseases, oncology, cardiology, nephrology, diabetes, and others. Among these, the infectious diseases segment to hold a significant share of the market in 2020. This is mainly due to the rising incidence of infectious diseases, that require early detection using these enzymes. For instance, according to the CDC/National Center for Health Statistics, 2022, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the US was 3.4 million. Therefore, infectious diseases such as typical pneumonia, TB, streptococcal pharyngitis, ulcerative urogenital infections, and a number of chronic conditions can be easily diagnosed with enzyme-based techniques like PCR.

Based on product type, the diagnostic enzymes market has been classified into molecular enzymes and clinical enzymes. The molecular enzymes category holds a major share of the market during the forecast period. This is mainly due to the rising research and adoption of molecular enzymes in molecular diagnostics. Different enzymes are mostly used through methods like PCR tests, NGS assays, and others. One of the most used molecular biology methods is PCR. The technology is being used more and more in a variety of industries, such as cloning, sequencing, forensic investigation, and diagnostic testing.

For a better understanding of the market adoption of the Diagnostic Enzymes industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increased need for enzymes and the rising incidence of infectious diseases in the region which has become dominant. In order to combat the continuing epidemic, the FDA has approved COVID-19 laboratory-developed diagnostics for emergency use. The majority of these emergency usage authorizations also make use of RT-PCR-based testing and enzyme-linked immunosorbent assays for the identification of SARS-CoV-2. The creation of such tests is anticipated to be profitable in the North American market because of the high usage of enzymes during RT-PCR.

Some of the major players operating in the market include: Takara Bio, Inc., Promega Corporation, Enzo Life Sciences, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., Creative Enzymes, F. Hoffmann-La Roche Ltd., Solis BioDyne, Ampliqon A/S, and Genzyme Corporation

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Diagnostic Enzymes Market
• 2.2. Research Methodology of the Diagnostic Enzymes Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DIAGNOSTIC ENZYMES MARKET

6 DIAGNOSTIC ENZYMES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Taq Polymerase
• 7.2. RNase Inhibitors
• 7.3. Cas9 Enzyme
• 7.4. Acid Phosphatase
• 7.5. Glucose Oxidase/Glucose Dehydrogenase
• 7.6. Urease
• 7.7. Lactate Oxidase
• 7.8. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Infectious Diseases
• 8.2. Autoimmune Diseases
• 8.3. Oncology
• 8.4. Cardiology
• 8.5. Nephrology
• 8.6. Diabetes
• 8.7. Others

9 MARKET INSIGHTS BY PRODUCT TYPE

• 9.1. Molecular Enzymes
• 9.2. Clinical Enzymes

10 MARKET INSIGHTS BY END USERS

• 10.1. Hospitals
• 10.2. Clinical Laboratories
• 10.3. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 DIAGNOSTIC ENZYMES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 DIAGNOSTIC ENZYMES MARKET OPPORTUNITIES

14 DIAGNOSTIC ENZYMES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Takara Bio, Inc.
• 18.2. Promega Corporation
• 18.3. Enzo Life Sciences, Inc.
• 18.4. Merck KGaA
• 18.5. Thermo Fisher Scientific, Inc.
• 18.6. Creative Enzymes
• 18.7. F. Hoffmann-La Roche Ltd.
• 18.8. Solis BioDyne
• 18.9. Ampliqon A/S
• 18.10. Genzyme Corporation

19 DISCLAIMER